SEC Form 4 · accession 0001562180-17-002919
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen A Holbrook
Director
Period of report
Sep 6, 2017
Accepted (ET)
Sep 8, 2017 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 6, 2017 | S | 1,059 | $121.7272 | D | 914 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $101.19 | holding | — | — | — | — | Oct 26, 2026 | Common Stock | 3,985 | 3,985 | D |
| Stock Option (right to buy) | $91.78 | holding | — | — | — | Oct 30, 2014 | Oct 30, 2024 | Common Stock | 4,000 | 4,000 | D |
| Stock Option (right to buy) | $87.39 | holding | — | — | — | Oct 31, 2013 | Oct 30, 2023 | Common Stock | 4,000 | 4,000 | D |
| Stock Option (right to buy) | $87.34 | holding | — | — | — | Oct 29, 2016 | Oct 28, 2025 | Common Stock | 4,260 | 4,260 | D |
| Stock Option (right to buy) | $70.35 | holding | — | — | — | Oct 27, 2011 | Oct 26, 2021 | Common Stock | 5,000 | 5,000 | D |
| Stock Option (right to buy) | $66.90 | holding | — | — | — | Oct 25, 2012 | Oct 24, 2022 | Common Stock | 5,000 | 5,000 | D |
| Stock Option (right to buy) | $65.47 | holding | — | — | — | Oct 23, 2008 | Oct 22, 2018 | Common Stock | 5,000 | 5,000 | D |
| Stock Option (right to buy) | $63.03 | holding | — | — | — | Oct 29, 2009 | Oct 28, 2019 | Common Stock | 5,000 | 5,000 | D |
| Stock Option (right to buy) | $61.46 | holding | — | — | — | Oct 28, 2010 | Oct 27, 2020 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.72 to $121.728, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders.